Plenary: Friday Morning
Hall D
Plenary
Information
Continuing Medical Education
CME
Format
On-Demand
Plenary: Friday Morning
Survivor Debate: How Do We Best Assess Prostate Cancer Patients on Active Surveillance for Disease Progression?
Friday, May 15, 2026 7:35 AM to 8:05 AM
Hall D
Crossfire: Controversies in Urology: Management of de Novo M1A PSMA-Pet Scan Positive Prostate Cancer
Friday, May 15, 2026 8:05 AM to 8:45 AM
Hall D
AUA-EAU Guidelines Panel Discussion: A Case-based Comparison of the Advanced Prostate Cancer Guidelines
Friday, May 15, 2026 8:45 AM to 9:15 AM
Hall D
Crossfire: Controversies in Urology: Bladder Preservation After Neoadjuvant Chemotherapy with Next Generation Treatments: Can Cystectomy be Avoided?
Friday, May 15, 2026 9:15 AM to 9:45 AM
Hall D
Ramon Guiteras Lecture: What Urologists Have Taught Us About Screening & Incidental Detection in Cancer (or at least, what they’ve taught me)
Friday, May 15, 2026 9:45 AM to 10:30 AM
Hall D
P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Durvalumab with bacillus Calmette–Guérin therapy for high-risk non-muscle-invasive bladder cancer: expanded efficacy and safety analyses from POTOMAC
Friday, May 15, 2026 10:30 AM to 10:40 AM
Hall D
P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: A non-viral intravesical gene therapy for BCG-unresponsive NMIBC with CIS, with or without papillary disease: pivotal phase 2 interim results of detalimogene voraplasmid
Friday, May 15, 2026 10:40 AM to 10:50 AM
Hall D
P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Intravenous Pembrolizumab Combined with Intravesical Bacillus Calmette–Guérin (BCG) for Patients with BCG-Naïve “Very High-Risk” T1 Non-Muscle Invasive Bladder Cancer Traditionally Reco
Friday, May 15, 2026 10:50 AM to 11:00 AM
Hall D
P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Darolutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): ARASEC – US prospective, open-label phase 2 study with an external control
Friday, May 15, 2026 11:00 AM to 11:10 AM
Hall D
P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Long-Term Oncological Outcomes of Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer: Phase 3 Randomized C
Friday, May 15, 2026 11:10 AM to 11:20 AM
Hall D
P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Extended follow-up shows accumulating benefit for patients treated with CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) in men with localized prosta
Friday, May 15, 2026 11:20 AM to 11:30 AM
Hall D
Documents & Links
Translations
Registered attendees
Kendrick Yim
Clinical FellowMoffitt Cancer Center